文献速递其他结缔组织病

转录组分层预测干燥综合征三种疗法的响应

Transcriptomic stratification predicts response to rituximab, abatacept, or the association of hydroxychloroquine and leflunomide in 3 randomised controlled clinical trials of Sjögren's disease.
PubMed 文献 · Ann Rheum Dis · 2025-12-24

该研究基于三项随机对照试验(HCQ-LEF、利妥昔单抗和阿巴西普)的临床与转录组数据,将170例干燥综合征患者分为4个转录组内型。

要点

  • 转录组内型可区分干燥综合征患者对HCQ-LEF和利妥昔单抗的差异响应。
  • 集群1患者活性治疗响应率显著优于安慰剂,利妥昔单抗试验呈类似趋势。
  • 健康样集群2患者对任何治疗均无显著响应,可能不适合纳入未来治疗试验。

核心结论

  • 干燥综合征患者转录组分层可揭示对HCQ-LEF和利妥昔单抗的差异治疗响应。
  • 健康样患者治疗响应极小,可能不适合作为未来治疗试验的候选人群。

研究设计与样本

  • 分析三项随机对照试验的临床、生物学和转录组数据:RepurpSS-I(HCQ-LEF,n=18)、TRACTISS(利妥昔单抗,n=56)和阿巴西普试验(n=117)。
  • 使用半监督均匀流形近似与投影结合支持向量机模型将患者分为4个转录组内型。
  • 在汇总和单项试验分析中比较各集群的人口学、疾病活动和基于Sjögren Tool for Assessing Response指数的治疗响应。

主要发现

  • 170例患者中,集群1至4分别有81、24、80和6例。
  • 集群3患者从HCQ-LEF获益,而集群2(健康样)对任何治疗均无显著响应。

临床怎么用

  • 转录组内型分型有望指导干燥综合征治疗选择,集群1可能优先考虑活性治疗。
  • 集群3患者可考虑HCQ-LEF治疗,健康样集群2患者可能不宜纳入治疗试验。

局限性

  • 各试验样本量较小,尤其集群4仅6例,可能影响统计效力。
  • 结论基于三项试验的回顾性分析,需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Sjögren's disease (SjD) is clinically and biologically heterogeneous, and no immunomodulatory drug has yet demonstrated efficacy in phase 3 trials. We previously identified 4 transcriptomic endotypes in SjD patients using whole-blood RNA sequencing. We hypothesised that these endotypes may predict differential therapeutic responses. METHODS: We analysed clinical, biological, and transcriptomic data from 3 randomised controlled trials evaluating hydroxychloroquine-leflunomide (HCQ-LEF; n = 18; RepurpSS-I trial), rituximab (RTX; n = 56; TRACTISS trial), and abatacept (n = 117). Patients were assigned to the 4 endotypes using semisupervised uniform manifold approximation and projection combined with a support vector machine model. Demographics, disease activity, and therapeutic response, as defined by the Sjögren Tool for Assessing Response index, were compared across clusters in both pooled and individual trial analyses. RESULTS: Of 170 patients, 81, 24, 80, and 6 were classified into clusters 1 to 4, respectively. European Alliance of Associations for Rheumatology (EULAR) Sjögren's Syndrome Patient Reported Index scores were comparable across clusters, while the EULAR Sjögren's Syndrome Disease Activity Index was significantly higher in clusters 3 and 4 vs clusters 1 and 2 (P = .003). In pooled analyses, patients in cluster 1 had significantly greater response rates with active treatment vs placebo (61.5% vs 32.6%: P = .016), with a similar trend in the RTX trial. In contrast, patients in cluster 3 benefitted from HCQ-LEF, whereas cluster 2 (healthy-like patients) showed no significant response to any therapy. CONCLUSIONS: Transcriptomic stratification of SjD patients revealed differential responses to HCQ-LEF and RTX. Notably, healthy-like patients exhibited minimal treatment response, suggesting they may be unsuitable candidates for future therapeutic trials.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Chevet B, Devauchelle-Pensec V, Pontarini E, et al. Transcriptomic stratification predicts response to rituximab, abatacept, or the association of hydroxychloroquine and leflunomide in 3 randomised controlled clinical trials of Sjögren's disease. Ann Rheum Dis. 2025. PMID: 41448992. doi:10.1016/j.ard.2025.11.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。